Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase
about
Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cellsIsolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissue-specific expressionPhosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptorImmunohistochemical localization of phosphodiesterase 2A in multiple mammalian speciesThe two GAF domains in phosphodiesterase 2A have distinct roles in dimerization and in cGMP bindingSelective up-regulation of PDE1B2 upon monocyte-to-macrophage differentiationIn Search of Enzymes with a Role in 3', 5'-Cyclic Guanosine Monophosphate Metabolism in PlantsThe human phosphodiesterase PDE10A gene genomic organization and evolutionary relatedness with other PDEs containing GAF domainsGenomic organization of the human phosphodiesterase PDE11A gene. Evolutionary relatedness with other PDEs containing GAF domainsMolecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2AIdentification and characterization of DdPDE3, a cGMP-selective phosphodiesterase from DictyosteliumCross-regulation of Phosphodiesterase 1 and Phosphodiesterase 2 Activities Controls Dopamine-mediated Striatal α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor TraffickingA phosphodiesterase 2A isoform localized to mitochondria regulates respirationDual acylation of PDE2A splice variant 3: targeting to synaptic membranesMembrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulumNerve growth factor inhibits PC12 cell PDE 2 phosphodiesterase activity and increases PDE 2 binding to phosphoproteins.Protective effects of phosphodiesterase 2 inhibitor on depression- and anxiety-like behaviors: involvement of antioxidant and anti-apoptotic mechanismsDdPDE4, a novel cAMP-specific phosphodiesterase at the surface of dictyostelium cells.The distribution of phosphodiesterase 2A in the rat brain.Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.In vivo assessment of local phosphodiesterase activity using tailored cyclic nucleotide-gated channels as cAMP sensors.Phosphodiesterases and adrenal Cushing in mice and humans.cGMP decreases surface NKCC2 levels in the thick ascending limb: role of phosphodiesterase 2 (PDE2).A common functional regulatory variant at a type 2 diabetes locus upregulates ARAP1 expression in the pancreatic beta cell.Clinical and molecular genetics of the phosphodiesterases (PDEs).Phosphodiesterases and cyclic GMP regulation in heart muscle.Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases.Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials.Towards selective phosphodiesterase 2A (PDE2A) inhibitors: a patent review (2010 - present).Cardiac Phosphodiesterases and Their Modulation for Treating Heart Disease.Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?Characterization of phosphodiesterase 2A in human malignant melanoma PMP cellsPhosphodiesterase-2 inhibitor reverses corticosterone-induced neurotoxicity and related behavioural changes via cGMP/PKG dependent pathway.Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells.Inhibition of PDE2A, but not PDE9A, modulates presynaptic short-term plasticity measured by paired-pulse facilitation in the CA1 region of the hippocampus.Pyrido[4,3-e][1,2,4]triazolo[4,3-a]pyrazines as Selective, Brain Penetrant Phosphodiesterase 2 (PDE2) Inhibitors.Dominant role of cAMP in regulation of microvessel permeability.PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.The Role of Phosphodiesterase-2 in Psychiatric and Neurodegenerative Disorders.
P2860
Q22010143-42E3443D-A21D-423D-BA5D-60C4C443C1B7Q22254649-8F314412-74FC-4509-A66D-BFFE7B7F4671Q24298550-8C3F2D83-DA72-4207-8840-721EC09D47B9Q24337499-2D333161-2E2E-4B6E-B868-068B6880D5E4Q24538689-869B2069-3E66-4350-B4B2-40458BB1AA03Q24557526-856A0B47-AFD5-483E-936F-E2A4C130FF73Q26747346-C49ECA6D-E2C9-4ED4-80BA-E9B09BF558A7Q28116175-F82EE082-28D0-4D28-9FE6-EC5497111237Q28140572-8D74B6A5-8F7F-477C-A609-3971CF4B82EFQ28268016-908C80F8-4138-4DB2-B5E0-FF5BD3C57ECEQ28347817-17BCF261-5E52-46A2-AB60-8E8F22A08B1CQ28392899-2BAD3E19-2920-4E58-A1CD-7E5FFC0FB72EQ28506723-E3779260-6C66-40C0-A02A-25F7DF57A781Q28511192-ACF3C097-3C61-44E3-9AA6-8A1A9121BBABQ28594129-EF5DE0D6-D69A-4710-9B55-FEE6F9ECD0EBQ31962204-BEF79004-333B-497F-811D-A7C8BCE15E00Q33821243-7288E1F5-D3EA-41EE-BEC3-151E5B45C003Q34518650-C939B8FC-A469-4E82-B823-806D63EC740FQ35538783-37426C9F-5DD2-458A-80C1-CB65E00BB220Q36334968-9ACCA225-657F-474C-A32A-C4851E907869Q36444920-0B45FADB-E705-4BDD-9785-8E5E2909FCD0Q36514530-8B8B20BF-4484-46E8-A14A-CC85C03C82E4Q36956706-835138F0-04EB-41C9-9481-BE6DE0DF01DFQ37592282-09EAE70C-7CCE-4DA5-AA74-15C3DA2ACDCAQ37657841-679F6E45-C058-4242-A836-6779EC47DD55Q38033089-EF6B8FBA-634F-46DB-A5BD-870689AAD8C7Q38205932-51C8D9F7-C7E9-42EE-A45E-68813F7AAFFCQ38670275-2BF7CB06-0328-4EAD-9FF7-EF3D78D9AE76Q38870312-396A4816-AB21-4F66-B16B-0DD6396B8008Q38992600-513021C8-B1D9-48E6-960B-45B4C7AEE627Q39072124-4F8D9BF5-59B5-4471-87A9-4EC5276CAE7DQ39199574-3C194745-A08C-4006-A11A-B561BF99DF62Q39304685-2AABE5B9-5EDA-4BB2-9242-14FB39BD642EQ39817182-12E2143C-A69B-4DF7-B90A-FB59171DE2ABQ40591756-633F5D73-2CF2-4190-A49D-2117FE086AEBQ40732525-7365C6E5-FA42-4007-AD51-0D21AAB5B8C3Q41150445-AB836335-9261-4A71-9BAC-CF9B47E68D13Q41728380-347B25C1-E946-4ED5-8342-939C4A886F54Q42325938-8354D77E-893F-465E-8564-3B49A4C95BB5Q45068634-3B0B9296-061B-46A8-B953-CC431265AB28
P2860
Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase
description
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1997
@ast
im Mai 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1997/05/20)
@sk
vědecký článek publikovaný v roce 1997
@cs
wetenschappelijk artikel (gepubliceerd op 1997/05/20)
@nl
наукова стаття, опублікована в травні 1997
@uk
مقالة علمية (نشرت في 20-5-1997)
@ar
name
Isolation and characterization ...... c nucleotide phosphodiesterase
@ast
Isolation and characterization ...... c nucleotide phosphodiesterase
@en
Isolation and characterization ...... c nucleotide phosphodiesterase
@nl
type
label
Isolation and characterization ...... c nucleotide phosphodiesterase
@ast
Isolation and characterization ...... c nucleotide phosphodiesterase
@en
Isolation and characterization ...... c nucleotide phosphodiesterase
@nl
prefLabel
Isolation and characterization ...... c nucleotide phosphodiesterase
@ast
Isolation and characterization ...... c nucleotide phosphodiesterase
@en
Isolation and characterization ...... c nucleotide phosphodiesterase
@nl
P2093
P3181
P1433
P1476
Isolation and characterization ...... c nucleotide phosphodiesterase
@en
P2093
G. J. Rosman
J. A. Beavo
K. Ferguson
K. Loughney
T. J. Martins
W. K. Sonnenburg
P3181
P356
10.1016/S0378-1119(97)00046-2
P407
P577
1997-05-20T00:00:00Z